Thiosemicarbazone-based compounds have attracted significant attention in recent years due to their potential as inhibitors of cancer cell proliferation. They not only exhibit strong antiproliferative effects but also possess antioxidant properties that are crucial in combating oxidative stress linked to cancer progression. This review highlights specific compounds that not only exhibit significantly higher antiproliferative activities but also demonstrate lower toxicity compared to traditional chemotherapy agents. This is important because it suggests that these compounds could provide better treatment options while reducing the side effects often associated with chemotherapy. A detailed analysis of the structure–activity relationships (SARs) reveals that the unique structural features of these compounds play a crucial role in their enhanced effectiveness. Understanding which molecular characteristics contribute to improved activity will be key for future compound design. The findings from this study emphasize the need for further exploration and development of these novel agents. By investigating their biological mechanisms and optimizing their structures, researchers can improve cancer treatment strategies, providing safer and more effective options for patients. Despite substantial previous research on thiosemicarbazones and isothiosemicarbazones, the field still holds many unknowns and opportunities for discovery. Studying coordination chemistry with 3d metal ions and strategically modifying their inner structures may lead to new compounds with promising biological activities and selectivity. Overall, exploring thiosemicarbazones and isothiosemicarbazones as innovative pharmacological agents against cancer could unlock their full potential, significantly enhancing cancer treatment protocols and improving patient survival rates.

Wirksamkeit eines Kombinationsarzneimittels aus Centaurii herba, Levistici radix und Rosmarini folium bei Urolithiasis: Ergebnisse einer offenen, randomisierten, Kohortenstudie Urolithiasis (Harnsteinleiden; Bildung von Konkrementen in den ableitenden Harnwegen) kann zu schmerzhaften, kolikartigen Schmerzen führen, wenn die Konkremente oder Steine die Harnwege blockieren. Pflanzliche Drogenzubereitungen spielen seit Langem eine bedeutsame Rolle in der Prophylaxe und Therapie des Harnsteinleidens. In einigen Studien wurde bereits die Wirkung des Phytopharmakons Canephron® N, einer fixen Kombination der Drogen Centaurii herba, Levistici radix und Rosmarini folium, bei der Urolithiasis gezeigt. In einer aktuellen offenen, randomisierten, monozentrischen Kohortenstudie wurde die Therapie mit Canephron® N als Add-on-Therapie untersucht. Das Phytopharmakon wurde 135 Patienten zusätzlich zur Standardtherapie verabreicht, die Daten dieser Kohorte wurden mit den Daten von 102 Patienten unter Standardtherapie verglichen. Canephron® N begünstigte die spontane Elimination von Konkrementen und verminderte die Leukozyturie, die insbesondere mit entzündlichen Prozessen im Harntrakt einhergeht. Die Anwendung der Kombination zur Prävention und/oder als Add-on-Therapie in Ergänzung der Standardtherapie der Urolithiasis erscheint gerechtfertigt. Urolithiasis describes the formation of calculi in kidney and efferent urinary passages. If these calculi jam urinary passages, it is often associated with typical spastic pain attacks. Certain herbal drugs play a special role in urolithiasis prophylaxis and treatment. The herbal medical product Canephron® N, a combination of Centaurii herba, Levistici radix and Rosmarini folium, is established in the therapy of urolithiasis, the indication is proven by some clinical studies. In a randomised open monocentric add-on cohort study, the efficacy of Canephron® N was investigated for the treatment of urolithiasis. The herbal medical product was administered in 135 patients additionally to standard therapy, for comparison 102 patients were treated with standard therapy only. Canephron® N favours the spontaneous elimination of small calculi and significantly decreases leucocyturia, especially associated with urinary infection. Therefore it is justified to suggest the combination for prevention and/or in addition to standard therapy of urolithiasis.

A transversal study based on 1,186 respondents’ group questioning was realized in order to study lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) prevalence in men from the Republic of Moldova. The basic tools used included IPSS (International Prostate Symptom Score) and IIEF-5 (International Index of Erectile Function) questionnaires as well as general questions to assess the presence of risk factors.

Three new copper(II) complexes, [Cu(1,10‐Phen)(L)] (1), [Cu(2,2′‐Bpy)(L)] (2) and [Cu(3,4‐Lut)(L)] (3), where H₂L=2‐[(2,4‐dihydroxyphenyl)methylidene]‐N‐(prop‐2‐en‐1‐yl)hydrazine‐1‐carbothioamide, 1,10‐Phen=1,10‐phenanthroline, 2,2′‐Bpy=2,2′‐bipyridine, 3,4‐Lut=3,4‐lutidine, have been synthesized and characterized by elemental analysis, FTIR spectroscopy and single crystal X‐ray crystallography (1, 2). All compounds are mononuclear. The introduction of a monodentate N‐heteroaromatic base (3,4‐dimethylpyridine) has led to a significant increase of antimicrobial activity against Gram‐negative Escherichia coli and antifungal activity against Candida albicans compared to the pro‐ligand and the precursor complex [Cu(L)H₂O]. The introduction of bidentate N‐heteroaromatic bases did not lead to such increase of antimicrobial and antifungal activities. Moreover, complex 3 surpasses the inhibitory activity of tetracycline toward Enterobacter cloacae and the inhibitory activity of fluconazole toward Candida parapsilosis and Cryptococcus neoformans. The study of antioxidant activity against cation radicals ABTS⋅⁺ showed that complexes 1–3 are more active than Trolox, but only introduction of the monodentate N‐heteroaromatic base (3,4‐dimethylpyridine) led to the increase of antioxidant properties compared to the precursor complex.